Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammatory diseases
Biotech
Expedition resupplies for ph. 2 COPD voyage with $165M series A
The new funding will fuel the Bay Area biotech’s Fosun-licensed DPP1 inhibitor in COPD and other neutrophil-driven inflammatory diseases.
Darren Incorvaia
Oct 9, 2025 9:50am
MoonLake stock sinks as high placebo rate eclipses ph. 3 results
Sep 29, 2025 8:05am
Odyssey saga continues with $213M series D
Sep 10, 2025 8:00am
Fosun rises again, beaming up 3rd biotech deal in 3 weeks
Aug 29, 2025 10:05am
Sitala seals $670M deal for Fosun immune disease drug
Aug 26, 2025 2:44pm
Celldex ends esophageal program despite hitting primary endpoint
Aug 20, 2025 6:42am
